Rilertinib Mesylate Tablets (Sanrisso®) – 100?mg × 20 Tablets per Bottle
$1.00
Rilertinib mesylate (Sanrisso®), developed by Nanjing Sanhome Pharmaceutical Co., Ltd., is a third-generation EGFR-TKI approved by China’s NMPA (Approval No. H20240020; Drug Code: 86901583000930). Each bottle contains 20 tablets of 100?mg each. Strictly for laboratory research use only—not for clinical or human use.
描述
Rilertinib Mesylate Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Rilertinib Mesylate Tablets (Sanrisso®) |
| Dosage | 100?mg per tablet × 20 tablets per bottle |
| Formulation | Oral film-coated tablet |
| Approval No. | China NMPA H20240020 |
| Drug Code | 86901583000930 |
| Manufacturer | Nanjing Sanhome Pharmaceutical Co., Ltd. |
| Intended Use | Laboratory research only—Not for human or veterinary use |
? Overview & Mechanism
Rilertinib mesylate (Sanrisso®) is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets activating mutations and the T790M resistance mutation in non-small cell lung cancer (NSCLC). It exhibits potent anti-tumor activity against EGFR-mutant NSCLC cell lines and tumor models.
? Research & Clinical Context
-
China NMPA Approval (Feb 2025): Approved for patients with EGFR T790M mutation-positive advanced or metastatic NSCLC after progression on prior EGFR-TKI therapy.
-
Phase III Trials: Demonstrated superior progression-free survival (PFS) compared to gefitinib in EGFR-mutant NSCLC patients.
? Research Applications
Ideal for:
-
EGFR pathway and T790M-resistance mechanisms
-
In vitro and in vivo NSCLC models
-
Drug resistance and combination therapy studies
-
Pharmacokinetic and pharmacodynamic profiling
? Handling & Storage
-
Storage: Store at 20–25?°C, sealed and protected from light and moisture.
-
Handling: Use appropriate laboratory personal protective equipment (PPE); avoid ingestion or inhalation.
? References
-
NMPA approval announcement (Feb 19, 2025)
-
Phase III trial results comparing rilertinib vs gefitinib
-
Drug mechanism and development synopsis
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 26 × 25 × 26 厘米 |
Rilertinib Mesylate Tablets (Sanrisso®) – 100?mg × 20 Tablets per Bottle 有 1 个评价
相关产品
-
Abiraterone Acetate Tablets (Hengrui) – 250?mg × 120 Tablets per Bottle Price comparison
Abiraterone acetate is a potent CYP17A1 inhibitor used clinically to suppress androgen synthesis in prostate cancer. Manufactured by Chengdu Shengdi Pharmaceutical Co., Ltd., with China NMPA approval under H20193205 (product code: 86980435000069). This product is for laboratory research and development use only—not for clinical or therapeutic use. $2.00 -
Ivodazumab Injection (lvonescimab) – 10?ml per Vial [For Laboratory Research Only]
Ivodazumab (Yidafang®) is a monoclonal antibody developed by Kangfang Pharmaceutical Co., Ltd., approved by China's NMPA (Approval No. S20240020; Drug Code: 86985204000011). Each vial contains 10?ml of the injectable formulation. Strictly for laboratory research use only—not for clinical or human use.
$1.00 -
Cetuximab NO1 Injection 100?mg/50?mL (Datalai) by Kelun Botai | EGFR?Targeted Biologic | Price comparison
Cetuximab NO1 Injection, 100?mg in 50?mL vial, is a biosimilar developed by Sichuan Kelun Botai Biopharma, branded as Datalai®. Approved in China (NMPA S20250006), this EGFR-targeting monoclonal antibody is ideal for laboratory or analytical research in oncology.
?? For laboratory research use only – Not for human consumption or therapeutic use. $1.00 -
Elranatamab Injection 76?mg/1.9?mL/Freeze-dried powder
Elranatamab (ELREXFIO®) is a BCMA-CD3 bispecific antibody used in multiple myeloma research. Supplied as a 76?mg/1.9?mL single-dose vial, manufactured by Pfizer. Approved by FDA (Aug?2023) and EMA (Dec?2023). Ideal for oncology, immunotherapy, and T?cell engager studies.
$1.00
?? For laboratory research use only – Not for human consumption or therapeutic use.
tinknocke –
The logistics was very fast, I received it in 8 days